Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.17 +11.9%	$1.81	$0.90 ▼ $3.42	$78.54M	0.94	70,250 shs	43,768 shs
BMEA Biomea Fusion	$1.65 +0.2%	$1.91	$1.29 ▼ $13.07	$62.37M	-0.13	1.16 million shs	1.29 million shs
LTUS Lotus Pharmaceuticals	$0.01 +4.5%	$0.01	$0.00 ▼ $0.01	$18.51M	-2.48	35,254 shs	25,000 shs
PYXS Pyxis Oncology	$1.12 -7.1%	$1.18	$0.83 ▼ $5.39	$68.14M	1.13	733,925 shs	503,969 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	+8.50%	+9.87%	+69.53%	-40.71%
BMEA Biomea Fusion	0.00%	-8.62%	-42.17%	-21.98%	-61.98%
LTUS Lotus Pharmaceuticals	0.00%	-1.41%	+18.64%	+27.04%	+112.12%
PYXS Pyxis Oncology	0.00%	+1.36%	-12.89%	+22.33%	-61.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.8842 of 5 stars	3.5	5.0	0.0	0.0	1.9	1.7	0.0
BMEA Biomea Fusion	2.5937 of 5 stars	3.6	1.0	0.0	0.0	2.5	2.5	0.6
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	1.2597 of 5 stars	3.4	1.0	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	314.75% Upside
BMEA Biomea Fusion	3.18	Buy	$21.40	1,193.83% Upside
LTUS Lotus Pharmaceuticals	0.00	N/A	N/A	N/A
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	707.17% Upside

Current Analyst Ratings Breakdown

Latest LTUS, ARMP, PYXS, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	15.19	N/A	N/A	($1.33) per share	-1.63
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	$16.15M	4.28	N/A	N/A	$2.03 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	N/A	N/A	-25.06%	8/12/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
LTUS Lotus Pharmaceuticals	$110K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)

Latest LTUS, ARMP, PYXS, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	BMEA Biomea Fusion	-$0.64	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.12	0.12
BMEA Biomea Fusion	N/A	2.25	2.25
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	7.75	7.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
BMEA Biomea Fusion	96.72%
LTUS Lotus Pharmaceuticals	N/A
PYXS Pyxis Oncology	39.09%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
BMEA Biomea Fusion	18.42%
LTUS Lotus Pharmaceuticals	N/A
PYXS Pyxis Oncology	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.19 million	5.61 million	Not Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
LTUS Lotus Pharmaceuticals	230	2.64 billion	N/A	Not Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable

LTUS, ARMP, PYXS, and BMEA Headlines

Recent News About These Companies

Pyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXS

July 3 at 8:54 AM | marketwatch.com

Pyxis Oncology Appoints New Principal Financial Officer

July 3 at 6:37 AM | tipranks.com

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2025 | globenewswire.com

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14

June 19, 2025 | finance.yahoo.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Brokerages

June 16, 2025 | marketbeat.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG

June 5, 2025 | marketbeat.com

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments

May 30, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)

May 22, 2025 | theglobeandmail.com

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | globenewswire.com

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

May 8, 2025 | baystreet.ca

Pyxis Oncology reveals promising preclinical data for cancer drug

April 27, 2025 | investing.com

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025 | globenewswire.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

April 23, 2025 | zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 2, 2025 | globenewswire.com

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

March 25, 2025 | globenewswire.com

Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)

March 24, 2025 | markets.businessinsider.com

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

March 20, 2025 | markets.businessinsider.com

Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)

March 18, 2025 | markets.businessinsider.com

Pyxis Oncology (PYXS) Gets a Hold from William Blair

March 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTUS, ARMP, PYXS, and BMEA Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.17 +0.23 (+11.86%)

As of 07/3/2025 05:00 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Biomea Fusion NASDAQ:BMEA

$1.65 +0.00 (+0.24%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$1.66 +0.01 (+0.36%)

As of 07/3/2025 04:34 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0070 +0.00 (+4.48%)

As of 07/3/2025 11:21 AM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

Pyxis Oncology NASDAQ:PYXS

$1.12 -0.09 (-7.08%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$1.12 0.00 (0.00%)

As of 07/3/2025 04:31 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time